Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

BACKGROUND AND OBJECTIVES: Novel immunotherapy-based combination treatments have drastically improved clinical outcomes for previously untreated patients with advanced/metastatic renal cell carcinoma (aRCC). This study aimed to assess the temporal trends in grade 3/4 adverse event (AE) rates and ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Geynisman, Daniel M., Burotto, Mauricio, Porta, Camillo, Suarez, Cristina, Bourlon, Maria T., Huo, Stephen, Del Tejo, Viviana, Du, Ella X., Yang, Xiaoran, Betts, Keith A., Choueiri, Toni K., McGregor, Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250488/
https://www.ncbi.nlm.nih.gov/pubmed/35696045
http://dx.doi.org/10.1007/s40261-022-01170-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250488/
https://www.ncbi.nlm.nih.gov/pubmed/35696045
http://dx.doi.org/10.1007/s40261-022-01170-6

Ejemplares similares